207 related articles for article (PubMed ID: 33158997)
1. Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.
Kowalczyk JT; Wan X; Hernandez ER; Luo R; Lyons GC; Wilson KM; Gallardo DC; Isanogle KA; Robinson CM; Mendoza A; Heske CM; Chen JQ; Luo X; Kelly AE; Difilippantinio S; Robey RW; Thomas CJ; Sackett DL; Morrison DK; Randazzo PA; Jenkins LMM; Yohe ME
Mol Cancer Ther; 2021 Feb; 20(2):307-319. PubMed ID: 33158997
[TBL] [Abstract][Full Text] [Related]
2. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
3. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
4. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
[TBL] [Abstract][Full Text] [Related]
5. ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.
Dai YH; Hung LY; Chen RY; Lai CH; Chang KC
Transl Res; 2016 Sep; 175():129-143.e13. PubMed ID: 27150054
[TBL] [Abstract][Full Text] [Related]
6. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
7. Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.
Mäki-Jouppila JH; Laine LJ; Rehnberg J; Narvi E; Tiikkainen P; Hukasova E; Halonen P; Lindqvist A; Kallio L; Poso A; Kallio MJ
Mol Cancer Ther; 2014 May; 13(5):1054-66. PubMed ID: 24748653
[TBL] [Abstract][Full Text] [Related]
8. A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent.
Baker SJ; Cosenza SC; Athuluri-Divakar S; Reddy MVR; Vasquez-Del Carpio R; Jain R; Aggarwal AK; Reddy EP
Mol Cell; 2020 Jul; 79(1):180-190.e4. PubMed ID: 32619468
[TBL] [Abstract][Full Text] [Related]
9. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
10. Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo.
Agoni L; Basu I; Gupta S; Alfieri A; Gambino A; Goldberg GL; Reddy EP; Guha C
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1180-7. PubMed ID: 24529717
[TBL] [Abstract][Full Text] [Related]
11. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Fan AC; O'Rourke JJ; Praharaj DR; Felsher DW
Expert Opin Investig Drugs; 2013 Nov; 22(11):1495-509. PubMed ID: 23937225
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
Komrokji RS; Raza A; Lancet JE; Ren C; Taft D; Maniar M; Wilhelm F; List AF
Br J Haematol; 2013 Aug; 162(4):517-24. PubMed ID: 23789936
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.
Malacrida A; Rigolio R; Celio L; Damian S; Cavaletti G; Mazzaferro V; Miloso M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360994
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effects of rigosertib in high-risk neuroblastoma.
Radke K; Hansson K; Sjölund J; Wolska M; Karlsson J; Esfandyari J; Pietras K; Aaltonen K; Gisselsson D; Bexell D
Transl Oncol; 2021 Aug; 14(8):101149. PubMed ID: 34118691
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Navada SC; Silverman LR
Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
Oncotarget; 2015 Aug; 6(24):20231-40. PubMed ID: 26008977
[TBL] [Abstract][Full Text] [Related]
17. [Anti-Tumor Effect of Rigosertib on HEL and K562 Cells and Its Related Mechanism].
Xu F; Chang CK; Li X; He Q; Wu LY; Zhang Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1362-1366. PubMed ID: 29070108
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
[TBL] [Abstract][Full Text] [Related]
19. Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma.
Hensch NR; Bondra K; Wang L; Sreenivas P; Zhao XR; Modi P; Vaseva AV; Houghton PJ; Ignatius MS
Mol Cancer Ther; 2023 Jan; 22(1):123-134. PubMed ID: 36162055
[TBL] [Abstract][Full Text] [Related]
20.
Dolgikh N; Hugle M; Vogler M; Fulda S
Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
